QuidelOrtho (QDEL) Scheduled to Post Quarterly Earnings on Thursday

QuidelOrtho (NASDAQ:QDEL - Get Free Report) is set to release its earnings data after the market closes on Thursday, November 7th. Analysts expect QuidelOrtho to post earnings of $0.30 per share for the quarter. Investors interested in registering for the company's conference call can do so using this link.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last posted its earnings results on Wednesday, July 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.15. QuidelOrtho had a negative net margin of 65.60% and a positive return on equity of 3.87%. The company had revenue of $637.00 million during the quarter, compared to analysts' expectations of $613.51 million. During the same quarter last year, the company posted $0.26 EPS. QuidelOrtho's quarterly revenue was down 4.2% compared to the same quarter last year. On average, analysts expect QuidelOrtho to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

QuidelOrtho Stock Performance

QDEL traded down $0.94 on Thursday, reaching $38.05. The company had a trading volume of 338,938 shares, compared to its average volume of 975,068. The stock has a market cap of $2.56 billion, a P/E ratio of -1.38 and a beta of 0.09. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.79 and a current ratio of 1.44. QuidelOrtho has a fifty-two week low of $29.74 and a fifty-two week high of $75.86. The company's fifty day moving average is $42.85 and its 200 day moving average is $40.45.

Insider Buying and Selling

In related news, major shareholder Carlyle Group Inc. sold 169,467 shares of QuidelOrtho stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $42.10, for a total value of $7,134,560.70. Following the transaction, the insider now directly owns 8,724,346 shares of the company's stock, valued at $367,294,966.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold 365,819 shares of company stock valued at $15,027,674 over the last quarter. 1.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on QDEL shares. Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 target price on shares of QuidelOrtho in a research note on Friday, August 16th. UBS Group began coverage on QuidelOrtho in a research report on Thursday, September 19th. They set a "neutral" rating and a $50.00 price objective on the stock. Finally, Craig Hallum upgraded shares of QuidelOrtho from a "hold" rating to a "buy" rating and upped their price target for the company from $40.00 to $57.00 in a research note on Thursday, September 5th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $58.83.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.